Regulations of Connecticut State Agencies
Sec. 21a-243-9. Controlled substances in schedule III The controlled substances listed in this regulation are included by whatever official, common, usual, chemical, or trade name designation in Schedule III: (a) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: (1) Benzphetamine; (2) Chlorphentermine; (3) Clortermine; (4) Phendimetrazine. (b) Unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system: (1) Any compound, mixture or preparation containing: Amobarbital, Secobarbital, Pentobarbital or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule; (2) Any suppository dosage form containing Amobarbital, Secobarbital, Pentobarbital or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository; (3) Any substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid, except those substances which are specifically listed in other schedules, except that the following analgesic products shall not be considered to be controlled substances: (A) Products containing a ratio of fifteen milligrams of long or intermediate acting barbiturates combined with at least one of the following: (i) 188 mg aspirin; (ii) 375 mg salicylamide; or (iii) 70 mg phenacetin, acetanilid or acetaminophen; (B) Products containing a ratio of fifteen milligrams of short acting barbiturates combined with at least one of the following: (i) 307 mg aspirin; (ii) 614 mg salicylamide; or (iii) 106 mg phenacetin, acetanilid or acetaminophen; (4) Any compound, mixture or preparation containing equal weights of both tiletamine and zolazepam or any salt thereof and not mixed with other psychoactive substances; (5) Chlorhexadol; (6) Embutramide; (7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States Food and Drug Administration approved drug product; (8) Ketamine or any salt thereof; (9) Lysergic acid; (10) Lysergic acid amide;
- 1- Regulations of Connecticut State Agencies
(11) Methyprylon; (12) Sulfondiethylmethane; (13) Sulfonethylmethane; (14) Sulfonmethane. (c) Buprenorphine. (d) Nalorphine. (e) Any material, compound, mixture or preparation containing limited quantities of any of the following narcotic drugs or any salts thereof: (1) Not more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium; (2) not more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts; (3) not more than 300 milligrams of dihydrocodeinone, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium; (4) not more than 300 milligrams of dihydrocodeinone, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts; (5) not more than 1.8 grams of dihydrocodeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit,with one or more active, nonnarcotic ingredients in recognized therapeutic amounts; (6) not more than 300 milligrams of ethylmorphine, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more ingredients in recognized therapeutic amounts; (7) not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts; (8) not more than 50 milligrams of morphine, or any of its salts, per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts. (f) Unless expressly intended for administration through implants to nonhuman species and approved for such use by the Federal Food and Drug Administration, any anabolic steroid including but not limited to, any of the following, or any isomer, ester, salt or derivative of the following that acts in the same manner on the human body: (1) 3[beta],17-dihydroxy-5a-androstane; (2) 3[alpha],17[beta]-dihydroxy-5a-androstane; (3) 5[alpha]-androstan-3,17-dione; (4) 1-androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-1-ene); (5) 1-androstenediol (3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene); (6) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene); (7) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene); (8) 1-androstenedione ([5[alpha]]-androst-1-en-3,17-dione);
- 2- Regulations of Connecticut State Agencies
(9) 4-androstenedione (androst-4-en-3,17-dione); (10) 5-androstenedione (androst-5-en-3,17-dione; (11) Boldenone; (12) Boldione; (13) Chlorotestosterone; (14) Clostebol; (15) Dehydrochlormethyltestosterone; (16) [Delta]1-dihydrotestosterone (a.k.a. ‘1-testosterone’) (17[beta]- hydroxy-5[alpha]- androst-1-en-3-one); (17) desoxymethltestosterone; (18) Dihydrotesterone; (19) Drostanolone; (20) Ethylestrenol; (21) Fluoxymesterone; (22) Formebulone; (23) Furazabol (17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]- furazan); (24) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one; (25) 4-hydroxytestosterone (4,17[beta]-dihydroxy-androst-4-en-3-one); (26) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxyestr-4-en-3- one); (27) Mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5-androstan-3- one); (28) Mesterolone; (29) Methandienone; (30) Methandranone; (31) Methandriol; (32) Methandrostenolone; (33) Methenolone; (34) 17[alpha]-methyl-3[beta], 17[beta]-dihydroxy-5a-androstane; (35) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5a-androstane; (36) 17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-4-ene; (37) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-methyl-4-hydroxy-17[beta]- hydroxyestr-4-en-3-one); (38) Methyldienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one); (39) Methyltrienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9-11-trien-3-one); (40) Methyltesterone; (41) Mibolerone; (42) 17[alpha]-methyl-[Delta]1-dihydrotestosterone (17b[beta]- hydroxy-17[alpha]- methyl-5[alpha]-androst-1-en-3-one) (a.k.a. ‘17- [alpha]-methyl-1-testosterone’); (43) Nandrolone; (44) 19-nor-4,9 (10)-androstadienedione; (45) 19-nor-4-androstenediol (3[beta], 17[beta]-dihydroxyestr-4-ene); (46) 19-nor-4-androstenediol (3[alpha], 17[beta]-dihydroxyestr-4-ene); (47) 19-nor-5-androstenediol (3[beta], 17[beta]-dihydroxyestr-5-ene); (48) 19-nor-5-androstenediol (3[alpha], 17[beta]-dihydroxyestr-5-ene); (49) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
- 3- Regulations of Connecticut State Agencies
(50) 19-nor-5-androstenedione (estr-5-en-3,17-dione; (51) Norbolethone (13[beta], 17[alpha]-diethyl-17[beta]-hydroxygon- 4-en-3-one); (52) Norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one); (53) Norethandrolone; (54) Norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3- one); (55) Normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one); (56) Oxandrolone; (57) Oxymesterone; (58) Oxymetholone; (59) Stenbolone (17[beta]-hydroxy-2-methyl-[5[alpha]]-androst-1-en-3- one); (60) Stanolone; (61) Stanozolol; (62) Testolactone; (63) Testosterone; (64) Tetrahydrogestrinone (13[beta], 17[alpha]-diethyl-17[beta]- hydroxygon-4,9,11- trien-3-one); (65) Trenbolone. (g) Chorionic gonadotropin. (h) Any quantity of the following substances having a depressant effect on the central nervous system, including their salts, isomers and salts of such isomers, and esters: (1) Gamma-hydroxy butyric acid if contained in a product for which an application has been approved under section 505 of the federal food, drug and cosmetic act; or (2) Gamma-butyrolactone. (Effective November 25, 1991; Amended March 6, 2000; Amended June 10, 2003; Amended June 10, 2011)
- 4-